News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
US FDA Warns of Muscle Harm When Ingredients in Heart Drugs Merck & Co., Inc., Abbott Laboratories Combine
August 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Aug 8 (Reuters) - U.S. health officials warned the public on Friday about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Merck & Co.
Food and Drug Administration (FDA)
Abbott Laboratories
MORE ON THIS TOPIC
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
May 21, 2025
·
5 min read
·
Michael N. Abrams
Rare diseases
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’
May 20, 2025
·
3 min read
·
Dan Samorodnitsky
Cardiovascular disease
Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza
May 20, 2025
·
2 min read
·
Tristan Manalac
Policy
The Memory Gap: How Forgotten Diseases Are Making a Dangerous Comeback
May 19, 2025
·
6 min read
·
Lori Ellis